At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 74 enrolled
Drug / intervention
BMS-986165drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-arm, Multi-Center, Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Japanese Subjects With Moderate-to-Severe Psoriasis
In Brief
A Phase 3 clinical trial evaluating BMS-986165 for Psoriasis. Completed, enrolled 74 participants across 27 sites.
Detailed Summary
The purpose of this study is to investigate BMS-986165 given to Japanese participants with moderate-to-severe psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartApr 2019
First PostedApr 2019
Primary CompletionMar 2021
TodayJul 2026
First PostedApr 23, 2019
Enrollment StartApr 10, 2019
Primary CompletionMar 24, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.2 years ago
Interventions
BMS-986165drug
Oral tablet administration